Millennium Management LLC Has $6.15 Million Position in Encompass Health Co. (NYSE:EHC)

Millennium Management LLC lowered its holdings in Encompass Health Co. (NYSE:EHC - Free Report) by 91.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 66,623 shares of the company's stock after selling 734,688 shares during the period. Millennium Management LLC owned about 0.07% of Encompass Health worth $6,153,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its holdings in Encompass Health by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 644,764 shares of the company's stock worth $59,544,000 after acquiring an additional 4,345 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Encompass Health during the fourth quarter valued at approximately $4,160,000. US Bancorp DE raised its holdings in shares of Encompass Health by 9.6% during the fourth quarter. US Bancorp DE now owns 1,380 shares of the company's stock valued at $127,000 after buying an additional 121 shares during the last quarter. New York State Teachers Retirement System raised its holdings in shares of Encompass Health by 0.3% during the fourth quarter. New York State Teachers Retirement System now owns 76,102 shares of the company's stock valued at $7,028,000 after buying an additional 200 shares during the last quarter. Finally, Farallon Capital Management LLC raised its holdings in shares of Encompass Health by 15,266.7% during the fourth quarter. Farallon Capital Management LLC now owns 461,000 shares of the company's stock valued at $42,573,000 after buying an additional 458,000 shares during the last quarter. Institutional investors own 97.25% of the company's stock.

Analyst Upgrades and Downgrades

EHC has been the topic of a number of recent analyst reports. KeyCorp lifted their price target on Encompass Health from $122.00 to $135.00 and gave the company an "overweight" rating in a report on Tuesday. UBS Group increased their target price on shares of Encompass Health from $117.00 to $130.00 and gave the company a "buy" rating in a research report on Monday, April 28th. Royal Bank of Canada increased their target price on shares of Encompass Health from $110.00 to $125.00 and gave the company an "outperform" rating in a research report on Monday, April 28th. Barclays raised their price objective on shares of Encompass Health from $118.00 to $129.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Finally, Truist Financial reiterated a "buy" rating and set a $135.00 price objective (up previously from $116.00) on shares of Encompass Health in a research note on Monday, April 28th. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Encompass Health currently has a consensus rating of "Buy" and a consensus target price of $122.71.

Insider Buying and Selling

In related news, insider Elissa Joy Charbonneau sold 4,279 shares of the firm's stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $116.61, for a total value of $498,974.19. Following the completion of the transaction, the insider now owns 11,958 shares of the company's stock, valued at approximately $1,394,422.38. This trade represents a 26.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Mark J. Tarr sold 118,384 shares of the firm's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $121.53, for a total transaction of $14,387,207.52. Following the completion of the transaction, the chief executive officer now directly owns 527,070 shares of the company's stock, valued at $64,054,817.10. This represents a 18.34% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 132,663 shares of company stock valued at $16,034,082. Company insiders own 2.00% of the company's stock.

Encompass Health Price Performance

Encompass Health stock traded up $0.47 during mid-day trading on Thursday, hitting $119.99. The company's stock had a trading volume of 552,940 shares, compared to its average volume of 699,372. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84. The stock has a market capitalization of $12.09 billion, a P/E ratio of 26.90, a P/E/G ratio of 2.31 and a beta of 0.91. Encompass Health Co. has a twelve month low of $82.74 and a twelve month high of $121.96. The stock's fifty day moving average price is $109.12 and its two-hundred day moving average price is $101.77.

Encompass Health (NYSE:EHC - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $1.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.18. The firm had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. The firm's quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.12 earnings per share. Research analysts forecast that Encompass Health Co. will post 4.8 earnings per share for the current year.

Encompass Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Tuesday, July 1st will be paid a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a yield of 0.57%. The ex-dividend date of this dividend is Tuesday, July 1st. Encompass Health's dividend payout ratio is 14.05%.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.